New York State's Medicaid program spent nearly $185 million on hepatitis C drugs during the second quarter of 2015, accounting for more than 6 percent of all drug spending.
That's up nearly 50 percent from the $124 million the state's insurance program for low-income New Yorkers spent during the first three months of the year, according to data released by the Centers for Medicare and Medicaid Services.
Drug prices have become the focus of national outrage, with presidential candidates from both sides of the aisle and a bipartisan group of lawmakers criticizing pharmaceutical companies for the exorbitant prices of new drugs, and exponential price increases for existing drugs
Read more....Labels: Gilead, Harvoni, HCV Treatment, New York Medicaid, Sofosbuvir